Table 1 Clinical characteristics of 138 aNSCLC patients receiving ICIs treatment
Clinical characteristics | Level | Overall (n = 138) |
|---|---|---|
Gender (%) | Female | 25 (18.1) |
Male | 113 (81.9) | |
Age (%) | < 65 | 76 (55.1) |
≥ 65 | 62 (44.9) | |
BMI (%) | < 24 | 38 (27.5) |
≥ 24 < 28 | 73 (52.9) | |
≥ 28 | 27 (19.6) | |
Smoking (%) | No | 49 (35.5) |
Yes | 89 (64.5) | |
ECOG PS (%) | < 2 | 104 (75.4) |
≥ 2 | 34 (24.6) | |
Distant metastasis (%) | No | 55 (39.9) |
Yes | 83 (60.1) | |
Histology (%) | Adenocarcinoma | 80 (58.0) |
Squamous | 46 (33.3) | |
Others | 12 (8.7) | |
PD-L1 (%) | < 1% | 13 (9.4) |
≥ 1%, < 50% | 28 (20.3) | |
≥ 50% | 27 (19.6) | |
Unknown | 70 (50.7) | |
TMB (%) | TMB-high | 15 (10.9) |
TMB-low | 18 (13.0) | |
Unknown | 105 (76.1) | |
Commodities (%) | Hypertension | 33 (23.9) |
Diabetes | 13 (9.4) | |
Coronary heart disease | 12 (8.7) | |
COPD | 10 (7.2) | |
Bronchiectasis | 14 (10.1) | |
Latent tuberculosis | 6 (4.3) | |
Hepatitis B | 11 (8.0) | |
Thyroid nodules | 16 (11.6) | |
Mutation types (%) | BRAF | 1 (0.7) |
EGFR | 7 (5.1) | |
EGFR + KARS | 2 (1.4) | |
EGFR + TP53 | 1 (0.7) | |
HER2 | 1 (0.7) | |
HER2 + PIK3CA | 1 (0.7) | |
KRAS | 2 (1.4) | |
MET | 1 (0.7) | |
PIK3CA | 1 (0.7) | |
TP53 | 5 (3.6) | |
No | 116 (84.1) | |
Treatment types (%) | Chemoimmunotherapy | 86 (62.3) |
Immunotherapy | 52 (37.7) | |
Treatment lines (%) | First line | 83 (60.2) |
Second line | 25 (18.1) | |
≥ 3 lines | 30 (21.7) | |
irAEs of any grade (%) | Non-irAEs | 63 (45.7) |
irAEs | 75 (54.3) | |
severe irAEs (%) | Non-Grade3/4 | 99 (71.7) |
Grade3/4 | 39 (28.3) | |
irAEs number (%) | 0 | 65 (47.1) |
1 | 47 (34.1) | |
2 | 18 (13.0) | |
3 | 5 (3.6) | |
≥ 4 | 3 (2.2) | |
irAEs types (%) | Thyroid disorders | 22 (15.9) |
Skin rash | 23 (16.7) | |
Diarrhea | 13 (9.4) | |
Hepatitis | 19 (13.8) | |
Renal | 7 (5.1) | |
Pneumonitis | 19 (13.8) | |
Cardiovascular | 8 (5.8) | |
Neurotoxicity | 1 (0.7) | |
Thrombocytopenia | 2 (1.4) | |
PFS (month, median [IQR]) |  | 11.0 (3.55–21.23) |
PFS status (%) | Non-recurrence | 44 (37.6) |
Recurrence | 73 (62.4) | |
Best overall response (%) | PD + SD | 51 (43.6) |
PR | 66 (56.4) |